Genetic Diseases, X-Linked: Clinical Trials

1,718 trials for Genetic Diseases, X-Linked, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

873 completed, 229 recruiting, 175 unknown, 171 terminated. 461 Phase 2, 326 Phase 1, 233 Phase 3, 217 Not applicable, 55 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2461Completed 227, Terminated 76, Recruiting 45, Active not recruiting 38, Unknown 33, Withdrawn 15, Enrolling by invitation 12, Not yet recruiting 12, Suspended 3
Phase 1326Completed 178, Terminated 47, Recruiting 34, Unknown 21, Active not recruiting 19, Withdrawn 14, Enrolling by invitation 6, Not yet recruiting 5, Suspended 2
Phase 3233Completed 134, Terminated 32, Active not recruiting 28, Recruiting 20, Unknown 7, Withdrawn 6, Enrolling by invitation 3, Not yet recruiting 3
Not applicable217Completed 113, Unknown 36, Recruiting 23, Not yet recruiting 18, Active not recruiting 9, Terminated 9, Enrolling by invitation 5, Withdrawn 4
Phase 455Completed 33, Recruiting 7, Terminated 6, Active not recruiting 3, Unknown 3, Withdrawn 3
Early Phase 120Active not recruiting 6, Completed 5, Recruiting 4, Terminated 3, Unknown 1, Withdrawn 1

Follow Genetic Diseases, X-Linked: new trials by email Literature Review of Genetic Diseases, X-Linked trials Research Report on Genetic Diseases, X-Linked

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Phase 2 / Phase 3Not yet recruitingFenix Innovation Group402027-07-012026-09-09
Lentiviral Gene Therapy for CGD
Infusion of lentiviral TYF-CGD-modified autologous stem cells - Chronic Granulomatous Disease
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-07-012026-11-02
SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection
Direct intravenous injection of ivlv-X1 lentiviral vector - SCID, X-Linked
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-302026-11-03
Lentiviral FIX Gene Therapy
YUVA-GT-F901 - Hemophilia B
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-11-02
IT and IV Lentiviral Gene Therapy for X-ALD
Intrathecal and intravenous LV gene therapy - X-linked Adrenoleukodystrophy
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-11-02
Multicomponent Pain Self-Management in Adults With Haemophilic Arthropathy
Multicomponent pain self-management programme - Hemophilic Arthropathy, Chronic Pain
Not applicableNot yet recruitingInvestigación en Hemofilia y Fisioterapia702027-03-012026-10-06
Ultrasound Assessment of Joint Health in Patients With Mild Hemophilia (Factor Levels 5-40%)
Joint Ultrasound (HEAD-US), Blood Sample for Coagulation Factor Measurement - Mild Hemophilia
Not applicableNot yet recruitingAssistance Publique - Hôpitaux de Paris1502027-02-012026-08-17
A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X Syndrome
S247240 Low dose, S247240 Middle dose, S247240 High dose - Fragile X Syndrome (FXS)
Phase 2Not yet recruitingInstitut de Recherches Internationales Servier (I.R.I.S.)1002027-01-252026-11-12
Outside the Cage (OTC) Robotic Esophagectomy
OTC MIE Esophagectomy - Esophageal Cancer
Phase 1Not yet recruitingCentre hospitalier de l'Université de Montréal (CHUM)312027-01-012026-03-18
Safety of Intraosseous Anaesthesia in Children With Haemophilia
Intraosseous Anaesthesia - Haemophilia A, Haemophilia B
Not applicableNot yet recruitingAnkara Yildirim Beyazıt University202027-01-012026-11-04
A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy
Brogidirsen - Duchenne Muscular Dystrophy, Exon 44
Phase 2Enrolling by invitationNS Pharma, Inc.202026-12-162026-11-17
Multimodal Study About Absence of Dp140 in Becker Muscular Dystrophy: Brain-muscle Imaging, Cognition and Muscle Function
Becker Muscular Dystrophy
Not yet recruitingInstitut de Myologie, France752026-12-152026-11-03
CD19-B Cell Depletion in PAIS-ME/CFS Patients
Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID)
Phase 2Not yet recruitingCharite University, Berlin, Germany382026-12-012026-07-24
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS
Codabakalner, Placebo - Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD)
Phase 2 / Phase 3Not yet recruitingSpinogenix1202026-12-012026-10-09
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Lucerastat - Fabry Disease
Phase 3RecruitingIdorsia Pharmaceuticals Ltd.162026-12-012026-11-03
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
SRX246, Placebo - Aggressive Behavior in Fragile X Syndome
Phase 2Not yet recruitingAzevan Pharmaceuticals802026-12-012026-10-30
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD)
Phase 1 / Phase 2RecruitingVanderbilt University Medical Center302026-12-012026-11-12
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
ELEVIDYS, Sirolimus, Glucocorticoids - Duchenne Muscular Dystrophy
Phase 4RecruitingSarepta Therapeutics, Inc.202026-11-302026-11-12
A Trial to Investigate the Efficacy and Safety of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy
Tegacorat - Duchenne Muscular Dystrophy (DMD)
Phase 2Not yet recruitingGrünenthal GmbH362026-11-302026-11-17
A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or B
Marstacimab - Hemophilia
RecruitingPfizer1002026-11-162026-11-17

Showing 20 of 1718. Sign in to see all of them.

Narrower conditions

Muscular Dystrophy, Duchenne (481)  ·  Hemophilia B (262)  ·  Fabry Disease (243)  ·  Hemophilia A (142)  ·  Fragile X Syndrome (115)  ·  Rett Syndrome (95)  ·  Muscular Dystrophies (91)  ·  Granulomatous Disease, Chronic (78)  ·  Mucopolysaccharidosis II (77)  ·  Adrenoleukodystrophy (63)  ·  Ornithine Carbamoyltransferase Deficiency Disease (59)  ·  Bulbo-Spinal Atrophy, X-Linked (57)  ·  Genetic Diseases, Inborn (50)  ·  Wiskott-Aldrich Syndrome (41)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1715)  ·  Genetic Diseases, Inborn (1668)  ·  Nervous System Diseases (1213)  ·  Nutritional and Metabolic Diseases (565)  ·  Metabolic Diseases (536)  ·  Neuromuscular Diseases (530)  ·  Musculoskeletal Diseases (525)  ·  Central Nervous System Diseases (512)  ·  Metabolism, Inborn Errors (486)  ·  Muscular Disorders, Atrophic (482)  ·  Muscular Diseases (478)  ·  Heredodegenerative Disorders, Nervous System (447)  ·  Brain Diseases (435)  ·  Hemic and Lymphatic Diseases (418)

Interventions

Factor IX (31)  ·  agalsidase beta (28)  ·  migalastat (28)  ·  agalsidase alfa (24)  ·  larazotide acetate (19)  ·  Busulfan (18)  ·  Alemtuzumab (17)  ·  Cyclophosphamide (15)  ·  Blood Specimen Collection (14)  ·  ataluren (14)  ·  fludarabine (14)  ·  idursulfase (14)  ·  Whole-Body Irradiation (12)  ·  eteplirsen (12)  ·  Prednisone (11)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (39)  ·  Novo Nordisk A/S (36)  ·  Pfizer (30)  ·  Sarepta Therapeutics, Inc. (27)  ·  Shire (27)  ·  Amicus Therapeutics (24)  ·  Assistance Publique - Hôpitaux de Paris (22)  ·  Genzyme, a Sanofi Company (20)  ·  Hacettepe University (20)  ·  PTC Therapeutics (19)  ·  Baxalta now part of Shire (17)  ·  CSL Behring (17)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (17)  ·  Cooperative International Neuromuscular Research Group (15)  ·  Novartis Pharmaceuticals (15)

Countries

United States (882)  ·  United Kingdom (294)  ·  France (247)  ·  Italy (229)  ·  Canada (199)  ·  Germany (187)  ·  Spain (179)  ·  Australia (140)  ·  Turkey (Türkiye) (117)  ·  Belgium (112)  ·  Netherlands (107)  ·  China (88)  ·  Japan (88)  ·  Brazil (72)  ·  Poland (70)

Top investigators

Elizabeth M Kang, M.D. (9)  ·  Dorothy K Grange, MD (6)  ·  Suk S De Ravin, M.D. (6)  ·  Craig McDonald, MD (5)

Results publications

PMID 40750723, PMID 27657681, PMID 37460385, PMID 25075835, PMID 26196195, PMID 40386832, PMID 20004776, PMID 23818196, PMID 24139498, PMID 24290292, PMID 24331379, PMID 27262745, PMID 36408876, PMID 25295500, PMID 30194931, PMID 30261899, PMID 32956407, PMID 33395098, PMID 35075289, PMID 36848635, PMID 37539981, PMID 38363467, PMID 39383458, PMID 39847314, PMID 41671094, PMID 42613652, PMID 17546030, PMID 19772971, PMID 21586746, PMID 23035069, PMID 23176611, PMID 24399845, PMID 25071871, PMID 25283752, PMID 25795794, PMID 25801175, PMID 26573217, PMID 26764156, PMID 26855682, PMID 27509102, PMID 30193840, PMID 31889231, PMID 32434278, PMID 32522498, PMID 32851872, PMID 32994552, PMID 34693725, PMID 34779542, PMID 34922648, PMID 35568815

NIH funding

2023 (19), 2009 (14), 2018 (12), 2019 (11), 2015 (10), 2025 (10), 2016 (9), 2017 (9), 2014 (7), 2008 (5), U54NS065768 (5), U54DK083908 (4), K23HD109375 (2), P30CA015704 (2), R44NS095423 (2)